Emerging therapies for dry eye disease

Introduction Dry Eye Disease (DED) is defined as a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and a vicious cycle of inflammation on the ocular surface. Despite its high prevalence and standing as one of the most common eye conditions seen by practitioners, the current treatment options available to patients have not proven adequate. Areas covered This review will discuss the burden of DED, its pathophysiology, as well as emerging therapies. These therapies include immunosuppressants, immunomodulators, anti-inflammatory drugs, and corticosteroids. The mechanisms of these drugs will be discussed, as well as their phase of development and results from recent clinical trials. The literature search was performed using PubMed, Cochrane Library, Web of Science, ClinicalTrials.gov, and the Springer AdisInsight database. Expert Opinion The optimal therapy for DED is associated with improved bioavailability, minimal ocular side effects, and effective dosing. The ideal treatment has not yet been established, but this paper outlines a number of promising therapies. Continued development of therapies targeting the inflammation cascade, as well as the establishment of objective markers to quantify DED severity, are important aspects in the progression of treatment.

Automated summary

Dry Eye Disease is a multifactorial disease characterized by a loss of tear film homeostasis and inflammation on the ocular surface. Current treatment options have not been adequate. Emerging therapies include immunosuppressants, immunomodulators, anti-inflammatory drugs, and corticosteroids, with a focus on improved bioavailability and minimal side effects. Continued development of therapies targeting inflammation cascade and objective markers for DED severity are important for the progression of treatment.